ABBV-706 Clinical Trials (2026): 4 Studies for Small Cell Lung Cancer & Advanced Solid Tumors
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
4 ABBV-706 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 2 indications (including Small Cell Lung Cancer & Advanced Solid Tumors) and 999 total planned enrollment. 1 Phase 3 ABBV-706 trial and 1 Phase 2 are listed. 2 ABBV-706 clinical trials are actively recruiting at 38 U.S. sites across 21 states. Most recent activity: NCT07155174 (Sep 2031).
Where to Participate: All ABBV-706 Trial Sites in the U.S. (38 sites across 21 states)
Every actively recruiting ABBV-706trial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| AL | Birmingham Hematology and Oncology Associates d/b/a Alabama Oncology /ID# 280063 | Birmingham35243 | NCT07365241 | Map |
| AL | Usa Mitchell Cancer Institute /ID# 280198 | Mobile36604 | NCT07365241 | Map |
| AZ | City Of Hope - Phoenix /ID# 281323 | Goodyear85338 | NCT07365241 | Map |
| CA | City of Hope National Medical Center /ID# 281322 | Duarte91010 | NCT07365241 | Map |
| CA | City of Hope - Orange County Lennar Foundation Cancer Center /ID# 281396 | Irvine92618 | NCT07365241 | Map |
| CT | Yale University School of Medicine /ID# 278181 | New Haven06510 | NCT07155174 | Map |
| FL | University of Florida College of Medicine /ID# 277496 | Gainesville32610 | NCT07155174 | Map |
| FL | Ocala Oncology Center /ID# 278269 | Ocala34474 | NCT07155174 | Map |
| FL | Orlando Health Cancer Institute /ID# 280418 | Orlando32806 | NCT07365241 | Map |
| FL | Moffitt Cancer Center /ID# 277573 | Tampa33612 | NCT07155174 | Map |
| GA | City Of Hope - Atlanta /ID# 279929 | Newnan30265 | NCT07365241 | Map |
| IL | OSF St. Francis Medical Center /ID# 279930 | Peoria61637-0001 | NCT07365241 | Map |
| IL | Springfield Clinic - First /ID# 281309 | Springfield62702 | NCT07365241 | Map |
| IL | City Of Hope - Chicago /ID# 281335 | Zion60099 | NCT07365241 | Map |
| IN | Fort Wayne Medical Oncology And Hematology /ID# 277336 | Fort Wayne46804 | NCT07155174 | Map |
| IN | Franciscan St. Francis Health /ID# 279788 | Indianapolis46237 | NCT07365241 | Map |
| KY | Baptist Health Lexington /ID# 277729 | Lexington40503 | NCT07155174 | Map |
| MA | Dana-Farber Cancer Institute /ID# 277732 | Boston02215 | NCT07155174 | Map |
| MI | Cancer And Hematology Centers Of Western Michigan - Grand Rapids /ID# 279955 | Grand Rapids49503 | NCT07365241 | Map |
| MN | Minnesota Oncology - Edina Clinic /ID# 280698 | Edina55435 | NCT07365241 | Map |
| MO | Missouri Cancer Associates /ID# 278299 | Columbia65201 | NCT07155174 | Map |
| NC | FirstHealth of the Carolinas- Speciality Center /ID# 279857 | Pinehurst28374 | NCT07365241 | Map |
| OH | University Hospitals Cleveland Medical Center /ID# 277556 | Cleveland44106 | NCT07155174 | Map |
| OH | Oncology Hematology Care - Fairfield /ID# 280641 | Fairfield45014 | NCT07365241 | Map |
| OR | Willamette Valley Cancer Institute and Research Center /ID# 280617 | Eugene97401 | NCT07365241 | Map |
| TN | Tennessee Cancer Specialists - Knoxville - Old Weisgarber Road /ID# 280619 | Knoxville37909 | NCT07365241 | Map |
| TN | University Of Tennessee Medical Center /ID# 279896 | Knoxville37920 | NCT07365241 | Map |
| TN | Baptist Memorial Hospital /ID# 281405 | Memphis38120 | NCT07365241 | Map |
| TN | SCRI Oncology Partners /ID# 279779 | Nashville37203 | NCT07365241 | Map |
| TN | Vanderbilt University Medical Center /ID# 280169 | Nashville37232 | NCT07365241 | Map |
| TX | The University of Texas MD Anderson Cancer Center /ID# 277929 | Houston77030 | NCT07155174 | Map |
| TX | The University of Texas MD Anderson Cancer Center /ID# 280070 | Houston77030 | NCT07365241 | Map |
| TX | Texas Oncology - Northeast Texas /ID# 280642 | Tyler75702 | NCT07365241 | Map |
| VA | Blue Ridge Cancer Care - Blacksburg /ID# 281583 | Blacksburg24060 | NCT07365241 | Map |
| VA | Virginia Cancer Specialists - Fairfax /ID# 278298 | Fairfax22031 | NCT07155174 | Map |
| VA | Shenandoah Oncology /ID# 280699 | Winchester22601 | NCT07365241 | Map |
| WV | West Virginia University Hospitals /ID# 279883 | Morgantown26506 | NCT07365241 | Map |
| WI | University of Wisconsin /ID# 279909 | Madison53792-0001 | NCT07365241 | Map |
ABBV-706 clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | available | Total |
|---|---|---|---|---|
| P1 | 1 | 1 | ||
| P2 | 1 | 1 | ||
| P3 | 1 | 1 | ||
| N/A | 1 | 1 |
Recruiting ABBV-706 clinical trials (2)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07155174 | SEZanneA Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer | P2 | Small Cell Lung Cancer | 180 | Nov 2025 |
| NCT07365241 | A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer | P3 | Small Cell Lung Cancer | 531 | Jul 2026 |
ABBV-706 clinical trials by indication
Small Cell Lung Cancer (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07155174 | SEZanne | P2 | recruiting | A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer |
| NCT07365241 | — | P3 | recruiting | A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer |
| NCT07310277 | — | N/A | available | Expanded Access to ABBV-706 |
Advanced Solid Tumors (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05599984 | IV | P1 | active not recruiting | Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors |
ABBV-706 pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| SEZanne | NCT07155174 | P2 | recruiting | Small Cell Lung Cancer | 180 | — |
All ABBV-706 trials (4)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07155174 | SEZanne | A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer | P2 | recruiting | 180 | AbbVie | Nov 2025 |
| NCT07365241 | A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer | P3 | recruiting | 531 | AbbVie | Jul 2026 | |
| NCT05599984 | IV | Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors | P1 | active not recruiting | 288 | AbbVie | Dec 2022 |
| NCT07310277 | Expanded Access to ABBV-706 | — | available | 0 | AbbVie | — |
ABBV-706 clinical trials: frequently asked questions
- How many ABBV-706 clinical trials are there?
- 4 ABBV-706 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 2 are actively recruiting participants.
- Are ABBV-706 clinical trials recruiting in 2026?
- Yes — 2 ABBV-706 trials are actively recruiting in 2026, with 38 U.S. sites across 21 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is ABBV-706 being studied for?
- ABBV-706 is being studied for Small Cell Lung Cancer, Advanced Solid Tumors. The trials are grouped by indication on this page.
- What phase is ABBV-706 in?
- ABBV-706 clinical trials span 1 Phase 3, 1 Phase 2, 1 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors ABBV-706 clinical trials?
- The lead sponsor across the most ABBV-706 trials is AbbVie. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming ABBV-706as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: